Clinical Trial: Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07610941) titled 'Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies' on May 14.

Brief Summary: The STARLYS trial is an adaptive, modular, Phase 1, open-label, multi-part, clinical trial evaluating MST-0312 in selected solid tumors. MST-0312 is a targeted bispecific antibody that is designed to locally stimulate the lymphotoxin beta receptor (LTBR) in order to boost the body's immune response to cancer. The LTBR pathway is important in forming tertiary lymphoid structures and high endothelial venules in tumors, which have been associated with improved patient outcomes. The purpose of this study is to dete...